Molecular Partners Toekomstige groei

Future criteriumcontroles 2/6

De winst van Molecular Partners zal naar verwachting dalen met 1.2% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 57.8% per jaar. De winst per aandeel zal naar verwachting groeien met 1.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -104.1% zijn.

Belangrijke informatie

-1.2%

Groei van de winst

1.7%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	57.8%
Toekomstig rendement op eigen vermogen	-104.1%
Dekking van analisten	Low
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

BST:6ML0 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CHF Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	26	-72	-74	-40	2
12/31/2025	5	-69	-77	-61	3
12/31/2024	5	-59	-71	-64	3
9/30/2024	6	-63	-63	-62	N/A
6/30/2024	8	-58	-63	-62	N/A
3/31/2024	7	-59	-60	-60	N/A
12/31/2023	7	-62	-60	-59	N/A
9/30/2023	9	-60	-58	-57	N/A
6/30/2023	9	-62	-63	-62	N/A
3/31/2023	20	-50	-63	-62	N/A
12/31/2022	190	118	117	119	N/A
9/30/2022	189	117	112	114	N/A
6/30/2022	190	118	111	113	N/A
3/31/2022	182	106	101	102	N/A
12/31/2021	10	-64	-92	-91	N/A
9/30/2021	9	-67	-71	-69	N/A
6/30/2021	6	-72	-55	-54	N/A
3/31/2021	7	-66	-47	-46	N/A
12/31/2020	9	-63	-31	-29	N/A
9/30/2020	11	-53	-47	-45	N/A
6/30/2020	14	-48	-58	-56	N/A
3/31/2020	17	-43	-30	-28	N/A
12/31/2019	20	-36	-3	-1	N/A
9/30/2019	17	-37	0	1	N/A
6/30/2019	14	-38	2	4	N/A
3/31/2019	12	-38	-20	-19	N/A
12/31/2018	10	-37	-43	-42	N/A
9/30/2018	17	-27	-41	-41	N/A
6/30/2018	23	-18	N/A	-39	N/A
3/31/2018	22	-24	N/A	N/A	N/A
12/31/2017	20	-25	N/A	-40	N/A
9/30/2017	17	-26	N/A	N/A	N/A
6/30/2017	16	-28	N/A	-38	N/A
3/31/2017	19	-22	N/A	N/A	N/A
12/31/2016	23	-19	N/A	-35	N/A
9/30/2016	27	-13	N/A	N/A	N/A
6/30/2016	31	-3	N/A	18	N/A
3/31/2016	30	-2	N/A	N/A	N/A
12/31/2015	29	0	N/A	26	N/A
9/30/2015	28	-6	N/A	N/A	N/A
6/30/2015	25	-11	N/A	-24	N/A
3/31/2015	26	-5	N/A	N/A	N/A
12/31/2014	27	-2	N/A	-11	N/A
12/31/2013	32	7	N/A	-14	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 6ML0 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 6ML0 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 6ML0 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 6ML0 ( 57.8% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van 6ML0 ( 57.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat 6ML0 binnen 3 jaar verliesgevend zal zijn.

Molecular Partners Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Molecular Partners AG Announces Executive Changes

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven